mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice

mRNA编码的HIV-1 Env三聚体铁蛋白纳米颗粒可诱导产生单克隆抗体,这些抗体能够中和小鼠体内的异源HIV-1分离株。

阅读:2
作者:Zekun Mu ,Kevin Wiehe ,Kevin O Saunders ,Rory Henderson ,Derek W Cain ,Robert Parks ,Diana Martik ,Katayoun Mansouri ,Robert J Edwards ,Amanda Newman ,Xiaozhi Lu ,Shi-Mao Xia ,Amanda Eaton ,Mattia Bonsignori ,David Montefiori ,Qifeng Han ,Sravani Venkatayogi ,Tyler Evangelous ,Yunfei Wang ,Wes Rountree ,Bette Korber ,Kshitij Wagh ,Ying Tam ,Christopher Barbosa ,S Munir Alam ,Wilton B Williams ,Ming Tian ,Frederick W Alt ,Norbert Pardi ,Drew Weissman ,Barton F Haynes

Abstract

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared with trimers alone for priming of broadly neutralizing antibody (bnAb) B cell lineages. The successful expression of complex multivalent nanoparticle immunogens with mRNAs has not been demonstrated. Here, we show that mRNAs can encode antigenic Env trimers on ferritin nanoparticles that initiate bnAb precursor B cell expansion and induce serum autologous tier 2 neutralizing activity in bnAb precursor VH + VL knock-in mice. Next-generation sequencing demonstrates acquisition of critical mutations, and monoclonal antibodies that neutralize heterologous HIV-1 isolates are isolated. Thus, mRNA-LNP can encode complex immunogens and may be of use in design of germline-targeting and sequential boosting immunogens for HIV-1 vaccine development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。